COVID-19 in chronic myeloid leukemia patients in Latin America.

This observational, multicenter study aimed to report the clinical evolution of COVID-19 in patients with chronic myeloid leukemia in Latin America. A total of 92 patients presented with COVID-19 between March and December 2020, 26% of whom were severe or critical. The median age at COVID-19 diagnosis was 48 years (22-79 years), 32% were 60 years or older, and 61% were male. Thirty-nine patients presented with at least one comorbidity (42.3%). Eighty-one patients recovered (88%), and 11 (11.9%) died from COVID-19. There was one case of reinfection. Patients with a major molecular response presented superior overall survival compared to patients with no major molecular response (91 vs. 61%, respectively; p = 0.004). Patients in treatment-free remission and receiving tyrosine kinase inhibitors showed higher survival rates than patients who underwent hematopoietic stem cell transplantation and those who did not receive tyrosine kinase inhibitors (100, 89, 50, and 33%, respectively; p < 0.001).

Clinical characteristics, management and mortality of patients hospitalized with COVID-19 in a reference hospital in Lima, Peru / Características clínicas, manejo y mortalidad de pacientes hospitalizados con COVID-19 en un hospital de referencia en Lima, Perú

The objective of this study was to describe the clinical characteristics, management and mortality of adult patients hospitalized by COVID-19 during the first fortnight of May 2020 at the Edgardo Rebagliati Martins National Hospital (Lima, Peru). A retrospective cohort was performed reviewing electronic medical records. Data from 152 patients was collected (68.4% male, average age: 58.7 years). It was found that 27.0% had close contact with a person with COVID-19, 64.2% came to the hospital with a critical illness, 91.4% received hydroxychloroquine and 96.1% received azithromycin, 23.7% entered the intensive care unit, and mortality was 18.8%. In conclusion, more than half of the patients came to this hospital with a critical illness, almost all received drugs that were initially seen as potentially useful but are not currently recommended for the management of COVID-19 in hospitalized, and mortality was similar to that reported in other countries.

El presente estudio tuvo por objetivo describir las características clínicas, manejo y mortalidad de pacientes adultos hospitalizados por COVID-19 durante la primera quincena de mayo del 2020 en el Hospital Nacional Edgardo Rebagliati Martins (Lima, Perú). Se realizó una cohorte retrospectiva revisando historias clínicas electrónicas. Se recolectaron datos de 152 pacientes (68,4% varones, edad promedio: 58,7 años). Se encontró que 27,0% tuvo contacto cercano con una persona con COVID-19, 64.2% llegó al hospital con una enfermedad crítica, 91,4% recibió hidroxicloroquina y 96,1% recibió azitromicina, 23,7% ingresó a la unidad de cuidados intensivos, y la mortalidad fue de 18,8%. En conclusión, más de la mitad de los pacientes acudieron a este hospital con una enfermedad crítica, casi todos recibieron fármacos que inicialmente fueron vistos como potencialmente útiles pero que actualmente no son recomendados para el manejo de COVID-19 en hospitalizados, y la mortalidad fue similar a lo reportado en otros países.